Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Venous Thrombosis I: Introduction01:30

Venous Thrombosis I: Introduction

2
Venous thrombosis, the most common disorder of the veins, involves the formation of a thrombus or blood clot associated with vein inflammation. It can be classified as either superficial vein thrombosis or deep vein thrombosis.Superficial Vein Thrombosis: This involves the formation of a thrombus in a superficial vein, usually the greater or lesser saphenous vein. Though less severe than deep vein thrombosis (DVT), SVT can lead to complications if untreated.Deep Vein Thrombosis (DVT): This...
2
Formation of the Platelet Plug01:22

Formation of the Platelet Plug

4.8K
The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
4.8K
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

625
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
625
Extrinsic and Intrinsic Pathways of Hemostasis01:20

Extrinsic and Intrinsic Pathways of Hemostasis

5.9K
Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
5.9K
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

2
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
2
Clot Retraction and Fibrinolysis01:16

Clot Retraction and Fibrinolysis

4.4K
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
4.4K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Structure-Guided Discovery and Biochemical Validation of Novel Small-Molecule Inhibitors Predicted to Target the CCHFV OTU Protease Y89-W99 Pocket.

International journal of molecular sciences·2026
Same author

Depth of neutrophil mobilization stratifies survival in ST-elevation myocardial infarction.

Nature cardiovascular research·2026
Same author

Functional Characterization of a Novel OTU-like Deubiquitinase from <i>Neospora caninum</i> and Discovery of Small-Molecule Inhibitors.

International journal of molecular sciences·2026
Same author

The clot stiffens: neutrophil serpin B3 in ischemic stroke.

Blood·2026
Same author

Functional Characterization of OTU Domain-Containing Deubiquitinases from Plant Pathogenic Fungi Reveals Distinct Immune Modulatory Mechanisms.

Journal of fungi (Basel, Switzerland)·2026
Same author

Impact of concomitant left-sided valve disease on outcomes following tricuspid valve transcatheter edge-to-edge repair: insights from EuroTR.

ESC heart failure·2026

Related Experiment Video

Updated: Jun 9, 2025

Comprehensive Analysis of Procoagulant Platelets Exhibiting Features of Necrosis, Apoptosis and Platelet Activation
04:37

Comprehensive Analysis of Procoagulant Platelets Exhibiting Features of Necrosis, Apoptosis and Platelet Activation

Published on: May 23, 2025

185

Procoagulant platelet activation promotes venous thrombosis.

Rainer Kaiser1,2, Robin Dewender1, Maité Mulkers1

  • 1Department of Medicine I, Ludwig Maximilian University Hospital, Ludwig Maximilian University Munich, Munich, Germany.

Blood
|October 23, 2024
PubMed
Summary

Procoagulant activation of platelets drives venous thrombosis. Targeting this platelet function, as with methazolamide, offers a novel therapeutic strategy for preventing venous thromboembolism without increasing bleeding risk.

More Related Videos

Procoagulant Platelet Characterization by Measuring Phosphatidylserine Exposure and Microvesicle Release from Human Purified Platelets
05:49

Procoagulant Platelet Characterization by Measuring Phosphatidylserine Exposure and Microvesicle Release from Human Purified Platelets

Published on: November 29, 2024

494
A Microfluidic Flow Chamber Model for Platelet Transfusion and Hemostasis Measures Platelet Deposition and Fibrin Formation in Real-time
09:38

A Microfluidic Flow Chamber Model for Platelet Transfusion and Hemostasis Measures Platelet Deposition and Fibrin Formation in Real-time

Published on: February 14, 2017

13.7K

Related Experiment Videos

Last Updated: Jun 9, 2025

Comprehensive Analysis of Procoagulant Platelets Exhibiting Features of Necrosis, Apoptosis and Platelet Activation
04:37

Comprehensive Analysis of Procoagulant Platelets Exhibiting Features of Necrosis, Apoptosis and Platelet Activation

Published on: May 23, 2025

185
Procoagulant Platelet Characterization by Measuring Phosphatidylserine Exposure and Microvesicle Release from Human Purified Platelets
05:49

Procoagulant Platelet Characterization by Measuring Phosphatidylserine Exposure and Microvesicle Release from Human Purified Platelets

Published on: November 29, 2024

494
A Microfluidic Flow Chamber Model for Platelet Transfusion and Hemostasis Measures Platelet Deposition and Fibrin Formation in Real-time
09:38

A Microfluidic Flow Chamber Model for Platelet Transfusion and Hemostasis Measures Platelet Deposition and Fibrin Formation in Real-time

Published on: February 14, 2017

13.7K

Area of Science:

  • Cardiovascular Biology
  • Hemostasis and Thrombosis
  • Platelet Physiology

Background:

  • Platelet aggregation is a target for cardiovascular disease prevention, but current therapies are less effective for venous thromboembolism.
  • Existing anticoagulation treatments for venous thromboembolism carry a high risk of bleeding complications.
  • Novel therapeutic strategies are needed to target venous thrombosis effectively and safely.

Purpose of the Study:

  • To investigate the role of platelet procoagulant activation (PA) in venous thrombosis.
  • To explore targeting platelet PA as a therapeutic strategy for venous thromboembolism.
  • To identify specific molecular pathways and potential drug targets involved in platelet PA.

Main Methods:

  • Quantified procoagulant platelets in patients with deep vein thrombosis (DVT) and pulmonary embolism.
  • Utilized mouse models of DVT to assess platelet PA in vivo.
  • Generated mice with platelet-specific deficiencies in cyclophilin D and transmembrane protein 16F pathways.
  • Administered methazolamide, a carbonic anhydrase inhibitor, to mice and evaluated its effect on platelet activity and thrombosis.
  • Assessed hemostasis in mice following methazolamide treatment.

Main Results:

  • Elevated levels of procoagulant platelets were observed in patients and mice with venous thromboembolism.
  • Procoagulant activation of platelets was detected within thrombi in both murine and human samples.
  • Mice deficient in key PA pathways (cyclophilin D, TMEM16F) showed resistance to venous thrombosis.
  • Methazolamide reduced platelet procoagulant activity and alleviated venous thrombosis in mice.
  • Methazolamide did not impair trauma-associated hemostasis.

Conclusions:

  • Platelet procoagulant function is essential for venous thrombus formation.
  • Targeting platelet procoagulant activity represents a promising therapeutic approach for venous thromboembolism.
  • Methazolamide demonstrates potential as a novel agent for preventing venous thromboembolism by inhibiting platelet PA.
  • This study identifies new pharmacologic strategies for managing venous thromboembolism with a potentially improved safety profile.